SafeBeat Rx is filing a provisional patent, brought on two advisory board members and cleared the first hurdle for possible inclusion in the 2021 Summer cohort at Y Combinator.
“I am being a little bit vague here because we’re filing a provisional right now,” CEO Rachita Navara M.D. told the 4thEst8 when asked about her technology. “SafeBeat Rx is developing novel technology to increase access to important, at times lifesaving, heart medication… We have a workable MVP.”
The St. Louis startup was formed in October 2020, and just crossed the 4thEst8 radar last week by taking the $500 prize in the Venture Cafe Pitch Night competition. This week the company got news that it cleared hurdles in other local grant competitions: Skandalaris Venture Competition and Washington University’s ‘Big Ideas’ competition. Navara was also invited to interview for inclusion in the summer cohort at Y Combinator.
“Apparently, coming to this finalist status… puts us in the top 5 percent of over 10,000 startup applications worldwide,” said Navara of the Y Combinator process. “Our company was competitively accepted into MIT Engine Blueprint Startup Development Program. We were also competitively selected into an NSF I-Corps cohort and have conducted intensive customer discovery.”
Advisory Board ‘Gets’
Joining the SafeBeat Rx scientific advisory board are Dr. Melvin Scheinman and Dr. Christine Albert. Scheinman is the first to perform catheter ablation in humans and is working to discover genes driving heart rhythm disorders. Albert is the president of the Heart Rhythm Society and an expert clinical trialist.
Lindsay Amos at Y Combinator told the 4thEst8 that applications are still open so they’re not releasing numbers, but she confirmed that SafeBeat Rx was asked to interview – and that is the first hurdle.
Links:
Skandalaris Venture Competition
On the 4thEst8:
Honored to be featured, thanks for supporting our journey!
http://www.SafeBeatRx.com